This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

European Pharma Law Academy
September 2025
Downing CollegeCambridge, UK

Marc Martens
Partner, Co-Head of the International Life Sciences and Healthcare Group at Bird & Bird
Speaker

Profile

As co-head of the International Life Sciences & Healthcare group and head of Bird & Bird's Regulatory, Public & Administrative Law group in Brussels, Marc Martens provides cutting edge strategic and regulatory advice to life sciences clients and represents them in litigation

He offers both contentious and non-contentious strategic advice to Belgian and international pharma, biotech and medical devices companies, public bodies and national and European industry associations facing complex regulatory frameworks.

His areas of expertise cover issues relating to life-cycle management, clinical trials and data, data exclusivity, marketing, price and reimbursement authorisations, and e-health together with data protection, distribution and advertising issues. He provides advice to biotech companies on issues regarding Advanced Therapy Medicinal Products as well as the legal and bioethical issues relating to research and use of human cells and tissues. He regularly represents clients before the national's jurisdictions as well as before the European Court.

His public and administrative law expertise covers the full range of sub practices in public procurement and related litigation, environmental law, REACH, RoHS, WEES and other Belgian and EU compliance issues.

Marc holds a law degree from the Vrije Universiteit Brussel (VUB), where he worked for four years as a research assistant, and a degree in public and administrative law from the University of Brussels. Before joining Bird & Bird, he was an expert adviser to the Vice-Prime Minister of Belgium for 3 years.

He speaks and publishes on life sciences regulatory topics and teaches an introduction to Biotech Law at the VUB. I'm also on the board of the Belgian Biotech organisation BIO.BE.

Agenda Sessions

  • Orphan Drugs: Regulation and Incentives

    13:55
  • More than a decade of ATMP Regulation: lessons learned and current issues

    12:25